Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK(+) Lung Cancer Patients with Poor Survival

Anaplastic lymphoma kinase (ALK) sequencing can identify resistance mechanisms and guide next-line therapy in ALK(+) non-small-cell lung cancer (NSCLC), but the clinical significance of other rebiopsy findings remains unclear. We analysed all stage-IV ALK(+) NSCLC patients with longitudinally assess...

Descripción completa

Detalles Bibliográficos
Autores principales: Christopoulos, Petros, Dietz, Steffen, Kirchner, Martina, Volckmar, Anna-Lena, Endris, Volker, Neumann, Olaf, Ogrodnik, Simon, Heussel, Claus-Peter, Herth, Felix J., Eichhorn, Martin, Meister, Michael, Budczies, Jan, Allgäuer, Michael, Leichsenring, Jonas, Zemojtel, Tomasz, Bischoff, Helge, Schirmacher, Peter, Thomas, Michael, Sültmann, Holger, Stenzinger, Albrecht
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356563/
https://www.ncbi.nlm.nih.gov/pubmed/30669647
http://dx.doi.org/10.3390/cancers11010124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356563/
https://www.ncbi.nlm.nih.gov/pubmed/30669647
http://dx.doi.org/10.3390/cancers11010124

Ejemplares similares